Bristol Myers buys Orum's Blood Cancer Therapy for up to $180M

Princeton, NJ, November 6, 2023 (Reuters) -- Bristol Myers Squibb (BMY.N) acquires an experimental therapy to treat a type of blood cancer for an upfront payment of $100 million and a total value of up to $180 million from Orum Therapeutics' a privately held company. The therapy has early stage study clearance from the FDA.

Read full article here.